 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

This is a signal that MACK's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Merrimack Pharmaceuticals (MACK, $12.78) RSI Indicator left the overbought zone on November 28, 2023

Merrimack Pharmaceuticals (MACK, $12.87) RSI Indicator left the overbought zone on November 24, 2023

Merrimack Pharmaceuticals (MACK, $12.77) RSI Indicator left the overbought zone on November 20, 2023

Merrimack Pharmaceuticals (MACK, $12.82) RSI Indicator left the overbought zone on November 17, 2023

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK  Get Free Report)s stock price crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of...

Merrimack Pharmaceuticals (NASDAQ:MACK) Stock Passes Above 200-Day Moving Average of $12.28

This price move could be a signal that MACK may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options...

Merrimack Pharmaceuticals (MACK, $12.5) price may drop as it broke higher Bollinger Band on Nov 03, 2023

This is a Bullish indicator signaling MACK's price could rise from here. Traders may explore going long the stock or buying call options...

Merrimack Pharmaceuticals (MACK, $12.36) Moving Average Convergence Divergence (MACD) Histogram turned positive on November 2, 2023

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(Merrimack or the Company)] today announced its third quarter 2023 financial results for the period ended September 30, 2023. During the third quarter...

Merrimack Reports Third Quarter 2023 Financial Results

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK  Get Free Report) was the target of a significant drop in short interest in the month of September. As of September 30th, there was short interest...

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Sees Large Drop in Short Interest

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK  Get Free Report)s stock price passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of...

Merrimack Pharmaceuticals (NASDAQ:MACK) Stock Price Passes Above 200-Day Moving Average of $12.30

Merrimack Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer. Its pipeline includes MM-131, MM-141, and MM-310. The company was founded by Anthony J. Sinskey, Gavin MacBeath, and Ulrik B. Nielsen in 1993 and is headquartered in Cambridge, MA.

Watchers	8,236
52-Wk Low	$10.10
52-Wk High	$13.15

Market Cap	$182.16M
Volume (M)	22,970.00
52-Wk High	$13.15
52-Wk Low	$10.10

MACK Merrimack Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals